Core Insights - Stereotaxis reported third-quarter financial results for 2025, highlighting a focus on commercial progress and regulatory advancements in surgical robotics for minimally invasive endovascular interventions [1][2]. Financial Performance - Total revenue for Q3 2025 was $7.5 million, with system revenue at $1.9 million and recurring revenue at $5.6 million, compared to $4.4 million and $4.8 million in the same quarter of the previous year [3]. - Gross margin for the quarter was 55%, with recurring revenue gross margin at 67% and system gross margin at 19%, affected by fixed overhead costs [4]. - Operating expenses were $10.7 million, including $4.1 million in non-cash charges, with adjusted operating expenses decreasing to $6.6 million from $7.2 million year-over-year [5]. - The operating loss was ($6.6) million, and the net loss was ($6.5) million, compared to ($6.3) million and ($6.2) million in the previous year [6]. Cash Position and Liquidity - As of September 30, 2025, Stereotaxis had cash and cash equivalents of $10.5 million and no debt, with an expected increase to $14.5 million following an upcoming financing closing [7]. Future Outlook - The company anticipates Q4 2025 revenue to exceed $9 million, with system revenue around $3 million and recurring revenue greater than $6 million, supporting over 20% annual revenue growth for 2025 [8]. - Sustained growth in both system and recurring revenue is expected in 2026, with quarterly revenue projected to surpass an average of $10 million [8][9].

Core Insights - Stereotaxis reported a 9% increase in revenue for Q1 2025, totaling $7.5 million compared to $6.9 million in Q1 2024, driven by a 29% growth in recurring revenue [3][8] - The company is focused on advancing its innovation strategy, with key commercial advances including the initial commercialization of MAGiC in Europe and successful demonstrations of the GenesisX robot [2][8] - Stereotaxis expects double-digit revenue growth for the full year 2025, with system revenue projected at $2-3 million per quarter and recurring revenue scaling to $7 million in Q4 2025 [8][9] Financial Performance - System revenue for Q1 2025 was $2.0 million, down from $2.6 million in Q1 2024, while recurring revenue reached $5.5 million, up from $4.3 million [3][13] - Gross margin for Q1 2025 was 54%, with recurring revenue gross margin at 68% and system gross margin at 15% [4][14] - Operating loss for Q1 2025 was ($5.9) million, compared to ($4.7) million in Q1 2024, with adjusted operating loss at ($2.7) million [6][14] Cash and Liquidity - As of March 31, 2025, Stereotaxis had cash and cash equivalents of $10.7 million and no debt [7][15] - The company anticipates reduced cash use in 2025 compared to 2024, supported by growing recurring revenue and stable operating expenses [9] Regulatory and Market Outlook - Stereotaxis is advancing multiple regulatory efforts with six active reviews and plans for additional submissions, aiming for significant adoption of GenesisX pending regulatory approval in the U.S. [2][8] - The company expects substantial growth in 2026, supported by anticipated regulatory milestones and initial commercial launches in 2025 [8]